OBJECTIVE: Familial hypocalciuric hypercalcemia (FHH) is considered a relatively benign condition characterized by elevated serum calcium with relatively low urinary calcium excretion. It typically results from an altered set point in calcium homeostasis originating from mutations in the calcium-sensing receptor (CASR), AP2S1, or GNA11 genes, which encode for the calcium-sensing receptor (CaSR), adaptor-related protein complex 2, and G-protein alpha-11 subunit, respectively. Despite numerous reports of novel variants in these genes associated with FHH, new variants continue to be discovered. METHODS: We describe a 20-year-old man with a family history of hypercalcemia who had clinical findings compatible with FHH and no evidence of multiple endocrine neoplasia who underwent CASR gene sequencing for evaluation of hypercalcemia. Parathyroid gland single-photon emission computerized tomography scan was normal. RESULTS: CASR gene sequencing revealed a previously unreported heterozygous intronic variant at position 1608+3A>G (chromosome 3: 121994892) resulting in a 77-residue deletion. His mother has a history of bipolar disorder and hyperparathyroidism with an adenoma found on imaging, yet our patient had no evidence of adenoma and therefore no surgical intervention was recommended. Given that CaSR plays a role in parathyroid growth, some variants in CASR may ultimately lead to parathyroid hypertrophy and be mistaken for primary hyperparathyroidism. CONCLUSION: Long-term clinical follow up will be helpful in understanding the ultimate effects of specific CASR mutations on parathyroid growth or progression to significant hypercalcemia.
OBJECTIVE: Familial hypocalciuric hypercalcemia (FHH) is considered a relatively benign condition characterized by elevated serum calcium with relatively low urinary calcium excretion. It typically results from an altered set point in calcium homeostasis originating from mutations in the calcium-sensing receptor (CASR), AP2S1, or GNA11 genes, which encode for the calcium-sensing receptor (CaSR), adaptor-related protein complex 2, and G-protein alpha-11 subunit, respectively. Despite numerous reports of novel variants in these genes associated with FHH, new variants continue to be discovered. METHODS: We describe a 20-year-old man with a family history of hypercalcemia who had clinical findings compatible with FHH and no evidence of multiple endocrine neoplasia who underwent CASR gene sequencing for evaluation of hypercalcemia. Parathyroid gland single-photon emission computerized tomography scan was normal. RESULTS: CASR gene sequencing revealed a previously unreported heterozygous intronic variant at position 1608+3A>G (chromosome 3: 121994892) resulting in a 77-residue deletion. His mother has a history of bipolar disorder and hyperparathyroidism with an adenoma found on imaging, yet our patient had no evidence of adenoma and therefore no surgical intervention was recommended. Given that CaSR plays a role in parathyroid growth, some variants in CASR may ultimately lead to parathyroid hypertrophy and be mistaken for primary hyperparathyroidism. CONCLUSION: Long-term clinical follow up will be helpful in understanding the ultimate effects of specific CASR mutations on parathyroid growth or progression to significant hypercalcemia.
Authors: Mika Yamauchi; Toshitsugu Sugimoto; Toru Yamaguchi; Shozo Yano; Junning Wang; Mei Bai; Edward M Brown; Kazuo Chihara Journal: J Bone Miner Res Date: 2002-12 Impact factor: 6.741
Authors: Fadil M Hannan; M Andrew Nesbit; Chen Zhang; Treena Cranston; Alan J Curley; Brian Harding; Carl Fratter; Nigel Rust; Paul T Christie; Jeremy J O Turner; Manuel C Lemos; Michael R Bowl; Roger Bouillon; Caroline Brain; Nicola Bridges; Christine Burren; John M Connell; Heike Jung; Eileen Marks; David McCredie; Zulf Mughal; Christine Rodda; Sherida Tollefsen; Edward M Brown; Jenny J Yang; Rajesh V Thakker Journal: Hum Mol Genet Date: 2012-03-14 Impact factor: 6.150
Authors: Fadil M Hannan; M A Nesbit; Paul T Christie; Willy Lissens; Bart Van der Schueren; Marie Bex; Roger Bouillon; Rajesh V Thakker Journal: Clin Endocrinol (Oxf) Date: 2010-12 Impact factor: 3.478